Tonix Pharmaceuticals Holding (TNXP) Net Cash Flow (2010 - 2026)

Tonix Pharmaceuticals Holding's Net Cash Flow history runs 17 years deep, the most recent figure standing at -$23.8 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 172.25% year-over-year to -$23.8 million in Q1 2026; TTM through Mar 2026 was $53.4 million, a 57.16% decrease from a year earlier, with the FY2025 full-year figure at $110.2 million, up 49.21% from the prior year.
• Net Cash Flow declined to -$23.8 million in Q1 2026 per TNXP's latest filing, from $18.5 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $70.5 million in Q4 2024 and bottomed at -$48.2 million in Q1 2023.
• The 5-year median for Net Cash Flow is -$6.4 million (2025), against an average of $427529.4.
• Biggest YoY gain for Net Cash Flow was 2318.45% in 2022; the steepest drop was 359.14% in 2022.
• Year by year, Net Cash Flow stood at -$19.7 million in 2022, then soared by 190.88% to $17.9 million in 2023, then soared by 293.03% to $70.5 million in 2024, then tumbled by 73.81% to $18.5 million in 2025, then plunged by 228.87% to -$23.8 million in 2026.
• Per Business Quant, the three latest TNXP Net Cash Flow figures stand at -$23.8 million (Q1 2026), $18.5 million (Q4 2025), and $65.1 million (Q3 2025).